Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have received an average recommendation of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $111.09.
CRL has been the subject of a number of analyst reports. Credit Suisse Group reaffirmed a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories Intl. in a research note on Monday, October 16th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research note on Tuesday, October 24th. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. SunTrust Banks reaffirmed a “buy” rating and set a $113.00 price objective on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Finally, Robert W. Baird set a $117.00 price objective on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Monday, November 13th.
In other Charles River Laboratories Intl. news, Director Robert J. Bertolini sold 3,609 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $110.22, for a total value of $397,783.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $0.29, for a total value of $37,990.00. Over the last three months, insiders sold 195,673 shares of company stock valued at $2,644,046. Insiders own 2.20% of the company’s stock.
Shares of Charles River Laboratories Intl. (CRL) opened at $101.74 on Tuesday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories Intl. has a 52-week low of $85.00 and a 52-week high of $119.05. The firm has a market capitalization of $4,725.26, a price-to-earnings ratio of 24.81, a PEG ratio of 1.46 and a beta of 0.74.
Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.14. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The business had revenue of $478.50 million during the quarter, compared to analysts’ expectations of $475.02 million. During the same period in the previous year, the firm earned $1.21 earnings per share. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. research analysts forecast that Charles River Laboratories Intl. will post 5.14 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/13/charles-river-laboratories-intl-inc-crl-given-average-recommendation-of-hold-by-brokerages.html.
About Charles River Laboratories Intl.
Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.
Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.